FMC Corporation reported its financial results for the second quarter of 2025, showing a slight increase in revenue and a significant drop in net income. The company recorded revenue of $1.051 billion, marking a 1% rise from $1.038 billion in Q2 2024. However, FMC's GAAP net income plummeted by 77% to $67 million, down from $295 million in the same quarter of the previous year. This decline was attributed to gains related to tax incentives recorded in the prior year. The adjusted EBITDA increased by 2% to $207 million, representing 19.7% of revenue, compared to $202 million or 19.4% of revenue in Q2 2024. Adjusted EPS rose by 10% to $0.69 from $0.63. The company noted a 2% organic growth in revenue, driven by strong cost favorability and high-single-digit growth in its portfolio sales, particularly from new active ingredients. FMC also faced FX headwinds affecting sales and EBITDA and a lower price due to adjustments in "cost-plus" contracts with diamide partners. FMC announced that it is in the process of selling its India commercial business, though it will continue to supply the buyer with its IP-protected products and retain global manufacturing operations in India, with the sale anticipated within the next year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.